{"filings":[{"id":1249517,"accession_number":"0001708599-26-000040","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2026-06-24T20:10:12+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Serina increases authorized common stock from 40M to 125M; equity plan expanded by 2M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common stock increased from 40,000,000 to 125,000,000 shares via filed certificate of amendment.","2024 Equity Incentive Plan share reserve raised by 2,000,000 shares to 5,210,478; evergreen start moved to FY2027.","Stockholders approved all eight proposals at annual meeting, including director elections and share increase."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":442476,"accession_number":"0001708599-26-000036","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2026-05-14T20:05:05+00:00","items":["2.02","9.01"],"status":"ready","headline":"Serina Therapeutics Q1 2026 net loss $6.9M; Phase 1b study of SER-252 underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $6.9M ($0.58 per share) for Q1 2026 vs. $4.8M ($0.49) in Q1 2025.","R&D expenses $3.2M, G&A $3.1M; total operating expenses $6.3M.","Cash and equivalents $24.5M at March 31, 2026; additional $5.2M from PIPE in April.","SER-252 Phase 1b registrational study underway; first patient dosed Feb 2026; TFL data from SAD arm expected H1 2027.","Closed $21.2M private placement in March/April 2026; Senior Convertible Note amended to remove further borrowing obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94876,"accession_number":"0001708599-26-000027","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"Serina appoints CTO, raises CEO salary to $500K, amends bylaws for Co-Chairs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Srini Tenjarla, Ph.D., promoted to CTO of Serina (AL) subsidiary; salary increased to $425,000 retroactive to Mar 15, 2026.","CEO Steve Ledger salary raised to $500,000 retroactive to Sept 9, 2024; retro payment made in lump sum Apr 2026.","Bylaws amended to allow one or more Co-Chairs with equal authority to call special meetings and preside."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107560,"accession_number":"0001708599-26-000018","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Serina Therapeutics reports FY2025 net loss of $19.4M; SER-252 Phase 1b initiated; up to $30M financing closed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $19.4M ($1.91/share) vs $11.1M ($1.51/share) in FY2024; operating expenses rose to $24.2M from $17.1M.","FDA IND cleared for SER-252 (advanced Parkinson's); first patient dosed in Phase 1b trial in February 2026.","Private placement of up to $30M closed; $16M received as of March 23, 2026; Greg Bailey appointed Co-Chairman.","ATM program raised $12.9M from 3.5M shares at avg $3.72; additional $10M raised in 2026.","Cash and cash equivalents $3.1M as of December 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107559,"accession_number":"0001708599-26-000010","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["1.01","3.02","5.02","5.03","7.01","9.01"],"status":"ready","headline":"Serina raises $15M first tranche (up to $30M) at $2.25/share (68% premium); Greg Bailey appointed Co-Chairman","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First tranche of $15M closed March 20, 2026; second tranche up to $15M due by April 30, 2026.","Pricing at $2.25 per share (68% premium to March 17 close); 50% warrant coverage at $5 exercise (273% premium).","Warrants if fully exercised could add up to $33.3M; total potential funds ~$63.3M to extend runway into 2H 2027.","Proceeds to fund SER-252 registrational trial for advanced Parkinson's; first patient dosed in SAD study.","Greg Bailey, M.D., lead investor, appointed Co-Chairman of Board; existing convertible note amended to eliminate further borrowing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107558,"accession_number":"0001708599-26-000005","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2026-01-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Serina Therapeutics receives FDA clearance for SER-252 IND in advanced Parkinson's","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND for SER-252, an investigational therapy for advanced Parkinson's disease.","Phase 1b registrational study to start; site and regulatory activities in Australia underway.","FDA alignment on 505(b)(2) NDA pathway provides clear development path for SER-252.","CEO Steve Ledger calls milestone a major step toward addressing significant unmet need."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107557,"accession_number":"0001708599-26-000003","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2026-01-15T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"Serina Therapeutics receives NYSE American deficiency notice for stockholders' equity below $2M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity was $1.6M as of Sept 30, 2025, below $2M, $4M, and $6M thresholds.","Company has until Feb 8, 2026 to submit a plan to regain compliance by July 9, 2027.","Non-compliance triggers NYSE American Section 1009; delisting proceedings may start if plan rejected.","Company intends to submit a plan but cannot assure compliance during the 18-month cure period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123921,"accession_number":"0001708599-25-000138","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Serina submits complete response to FDA clinical hold for SER-252 Parkinson's program","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Complete response submitted Dec 9, 2025, addressing FDA's clinical hold on SER-252 related to trehalose excipient.","Submission includes detailed data package on trehalose as subcutaneous excipient and revised protocol for SAD phase.","FDA clinical hold does not involve apomorphine drug substance, mechanism of action, enFuse device, or 505(b)(2) pathway.","Global site start-up continues; first-patient-in for Phase 1b registrational study targeted for Q1 2026, subject to hold resolution.","Company acknowledges FDA's engagement and expects SAD phase initiation in Q1 2026 pending regulatory and ethics approvals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123920,"accession_number":"0001708599-25-000135","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Serina Therapeutics Q3 net loss $4.6M; FDA places SER-252 on clinical hold","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.6M ($0.45 per share) vs net income of $1.4M in Q3 2024.","FDA placed IND for SER-252 on clinical hold due to excipient question; not related to active drug.","Secured up to $20M convertible note/warrant financing; first $5M drawn in September 2025.","ATM program raised $2.8M net; 474,712 shares issued at avg $6.00 per share.","Cash $8.6M as of Sept 30; R&D expenses rose to $3.6M from $2.4M year-over-year."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":130000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123919,"accession_number":"0001708599-25-000130","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Serina Therapeutics stockholders elect directors and ratify auditors at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Steve Ledger and Karen J. Wilson elected as directors with over 4.1M votes For each.","Ratification of Frazier & Deeter as independent auditor approved: 6.54M For, 378K Against.","Approval of convertible note and warrants issuance passed: 4.15M For, 108K Against.","Broker non-votes of 2.68M present on director election and note/warrants proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123918,"accession_number":"0001708599-25-000126","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Serina Therapeutics announces FDA clinical hold on SER-252 IND for advanced Parkinson's disease","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA placed clinical hold on SER-252 IND, requesting additional info on a commonly used excipient; not related to active drug or mechanism.","Serina expects formal clinical-hold letter within 30 days and will work expeditiously with FDA to address requests.","FDA previously indicated support for SER-252 development under 505(b)(2) NDA pathway; CEO remains confident in program.","SER-252 is Serina's lead program for advanced Parkinson's; Phase 1b trial designed as randomized, double-blind, placebo-controlled."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123917,"accession_number":"0001708599-25-000122","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Serina Therapeutics draws first $5M tranche from $20M note for SER-252 Parkinson's trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received $5 million initial tranche under up to $20 million convertible note financing agreement.","Proceeds to fund registrational Phase 1b trial of SER-252 for advanced Parkinson's disease.","IND submitted to FDA and HREC approval received in Australia; global trial initiation in Q4 2025.","Phase 1b trial design: randomized, double-blind, placebo-controlled with SAD (n=40) and MAD (n=48) cohorts.","Subsequent tranches tied to development milestones including patient enrollment in the clinical trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140592,"accession_number":"0001708599-25-000110","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2025-09-15T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Serina Therapeutics enters up to $20M convertible note from director Gregory H. Bailey for clinical study SER-252-1b","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Up to $20M drawn in 5 tranches tied to milestones for SER-252-1b registrational study; $5M available by Sept 30, 2025.","10% annual interest; conversion at $5.18/share; warrants at $5.44/share for 100% of conversion shares.","Lender is Dr. Gregory H. Bailey, board member and affiliate of largest shareholder Juvenescence; approved by independent special committee.","Senior unsecured; prepayable at any time without penalty; mandatory repayment on change of control or liquidity event.","Maturity 5 years from initial funding; customary events of default with 2% default interest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140591,"accession_number":"0001708599-25-000108","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Serina Therapeutics Secures Up to $20M in Convertible Note for Parkinson's Trial","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Unsecured convertible note up to $20M in five tranches tied to clinical milestones; first $5M available by Oct 1, 2025.","Convertible at $5.18/share (9/8 close), 10% annual interest payable quarterly after first year, 5-yr maturity.","Each tranche carries 100% warrant coverage at $5.44/share; warrants expire 60 days after first Cohort 2 dose or Sept 30, 2026.","Proceeds to advance SER-252 Phase 1b registrational trial for advanced Parkinson's under 505(b)(2) NDA path.","IND submission planned Q4 2025; dosing in Australia Q4 2025 and U.S. initiation Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140590,"accession_number":"0001708599-25-000105","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2025-08-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA feedback supports registrational trial for SER-252 in advanced Parkinson's under 505(b)(2) NDA pathway","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA Type B meeting written feedback supports advancing SER-252 (POZ-apomorphine) in registrational study.","Plans to submit U.S. IND in Q4 2025; patient dosing in Australia expected to start in Q4 2025.","U.S. enrollment expected to begin in Q1 2026 after IND clearance.","SER-252-1b study is randomized, double-blind, placebo-controlled Phase 1b with up to 88 patients.","CEO highlights capital-efficient 505(b)(2) pathway; platform may apply to other POZ-enabled small molecules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140589,"accession_number":"0001708599-25-000101","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2025-08-22T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Serina Therapeutics amends bylaws to add safe harbor procedures and expand forum selection clause","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board adopted Bylaws Amendment on August 18, 2025, effective immediately.","Adds safe harbor procedures for transactions involving interested directors, officers, or control groups.","Expands forum selection clause to cover stockholder claims related to corporate business or governance.","Amendment supplements Section 9.2 of the Amended and Restated Certificate of Incorporation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140588,"accession_number":"0001708599-25-000091","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Serina Therapeutics Q2 net loss $6.4M; cash runway into Q4 2025; SER-252 on track for clinic this year","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $6.4M ($0.66/share) vs prior-year net income $5.2M ($0.61/share).","Revenue $130k (NIH grants) vs $51k YoY; R&D spend up 100% to $3.2M.","Cash $6.0M; projects funding into Q4 2025; raised $1.2M net via ATM at avg $5.95.","Lead candidate SER-252 (POZ-apomorphine) on track for Phase 1 in Q4 2025.","Advanced SER-270 (once-weekly injectable) for tardive dyskinesia; appointed Dr. Brannan to board."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":130000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140587,"accession_number":"0001708599-25-000076","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Serina advances SER-270 (POZ-VMAT2i) once-weekly injectable into TD development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SER-270 is a long-acting, once-weekly subcutaneous VMAT2 inhibitor for tardive dyskinesia (TD).","U.S. TD market reached $3.7B in 2024; projected to grow to $5.4B by 2030.","Fewer than 30% of U.S. TD patients are diagnosed; less than half receive treatment.","Serina plans to explore POZ-VMAT2i for Huntington's chorea as a secondary indication.","CEO Steve Ledger to present at BTIG Virtual Biotechnology Conference on July 29, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140586,"accession_number":"0001708599-25-000065","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["5.08","8.01","7.01","9.01"],"status":"ready","headline":"Serina Therapeutics sets 2025 annual meeting for Nov 7; updates proposal deadlines","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting scheduled for November 7, 2025; location and time in proxy.","Rule 14a-8 stockholder proposals must be received by August 15, 2025.","Director nominations and other proposals due August 9, 2025; earliest July 10.","Meeting date change of >30 days from 2024 anniversary triggers adjusted deadlines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158297,"accession_number":"0001708599-25-000058","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["5.02","5.03","7.01","9.01"],"status":"ready","headline":"Serina appoints ex-Karuna CMO Brannan to board; director Gross departs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Dr. Stephen Brannan (former Karuna CMO) to board and Compensation Committee, effective May 22, 2025.","Brannan led clinical strategy for KarXT, first new schizophrenia mechanism in >30 years, key to Karuna's $14B BMS acquisition.","Remy Gross departed board effective May 22, 2025; no disagreement, stays as consultant.","Filed certificate of correction to Series A Preferred Stock to add conversion price adjustment reference."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158296,"accession_number":"0001708599-25-000055","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Serina Therapeutics Q1 net loss $4.8M; cash runway through Q3 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss attributable to Serina of $4.8M ($0.49/share) vs $15.0M ($5.38/share) in Q1 2024.","Cash and cash equivalents $4.3M at March 31, 2025; plus $5M April private placement extends runway through Q3 2025.","On track to dose first patient in Phase 1b trial of SER-252 for advanced Parkinson's in Q4 2025.","Secured $15M in equity financing since late 2024, including $10M from JuvVentures and $5M private placement.","Appointed Karen J. Wilson and Dr. Jay Venkatesan to the Board; POZ-lipid data showed no antibody response in rats."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158295,"accession_number":"0001708599-25-000048","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Serina Therapeutics enters ATM facility for up to $13.3M common stock sale","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Capital on Demand Sales Agreement with JonesTrading for at-the-market offering of up to $13,270,500 in common stock.","JonesTrading will receive 3.0% commission on gross sales; company also reimburses up to $50,000 in legal expenses.","Sales will occur on NYSE American or other trading markets at the company's direction; no minimum obligation to sell.","Updated description of capital stock filed as Exhibit 4.1 to reflect recent certificate of designations.","Proceeds intended for general corporate purposes; offering registered on Form S-3 (File No. 333-286340)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158294,"accession_number":"0001708599-25-000044","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2025-04-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Serina presents POZ-lipid LNP data showing no immune response in rats, solving PEG antibody issue","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["POZ-lipid did not trigger IgM or IgG response after repeat dosing in rats in a vaccine format.","PEG-lipid standard elicited a strong, boosted antibody response under same conditions.","Anti-PEG antibodies linked to anaphylaxis in mRNA vaccines; POZ-lipid offers immune-silent alternative.","Data presented at 4th LNP Formulation & Process Development Summit on April 15, 2025.","Discovery could enable safer LNP formulations for gene therapy and RNA medicines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158293,"accession_number":"0001708599-25-000042","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2025-04-14T23:59:59+00:00","items":["1.01","3.02","3.03","5.03","7.01","9.01"],"status":"ready","headline":"Serina Therapeutics raises $5M via convertible preferred stock for Parkinson's drug SER-252","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 962,250 shares of Series A Convertible Preferred at $5.18/share for ~$5M gross proceeds.","Preferred stock carries 8% cumulative annual dividend, paid in kind; convertible at $5.18 per common share.","Proceeds to support SER-252 (POZ-apomorphine) Phase 1 trial initiation in Q4 2025 for advanced Parkinson's.","Financing from strategic shareholders; conversion triggers include stock price doubling or $20M+ equity raise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158292,"accession_number":"0001708599-25-000033","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2025-04-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Serina Therapeutics CEO to present at Jones Healthcare and Technology Innovation Conference on April 9","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Steve Ledger will present at the conference in Las Vegas, NV on April 9, 2025 at 3:00 p.m. PDT.","A live webcast will be accessible via wsw.com; replay available for 90 days.","Presentation materials include POZ Platform overview covering small molecules, RNA, and ADCs.","No financial results or material operational updates were disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176676,"accession_number":"0001708599-25-000029","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Serina Therapeutics posts FY 2024 net loss of $11.1M vs net income of $5.3M in 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenues fell to $56K from $3.2M; operating expenses rose to $17.1M from $6.3M.","Cash and equivalents $3.7M at Dec 31, 2024; plus $5M from JuvVentures in Jan 2025, projected to fund through Q2 2025.","R&D expense increased $5.1M to $7.5M, driven by SER-252 development and higher headcount.","Sold UniverXome subsidiary in Dec 2024, eliminating $11.2M debt; $10M equity financing from JuvVentures secured.","Appointed Karen J. Wilson and Dr. Jay Venkatesan to board; targeting first patient in Phase 1b trial for SER-252 in Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176675,"accession_number":"0001708599-25-000023","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Serina presents non-immunogenic POZ-lipid data at ACS 2025 meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Randall Moreadith, M.D., Ph.D., Chief Development Officer, presented at ACS Spring 2025 in San Diego.","Presentation titled 'A Non-Immunogenic LNP for Gene Delivery: Characterization of Poly(oxazoline) Lipid Nanoparticles'.","In rats, POZ-lipid did not trigger IgM or IgG antibody response after repeat dosing.","In contrast, PEG-lipid standards elicited a strong and boosted antibody response.","Non-immunogenic POZ-lipid could enable safer LNP formulations for gene therapy and RNA medicines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176674,"accession_number":"0001708599-25-000016","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Serina Therapeutics appoints Dr. Jay Venkatesan to board; Dr. Milton Harris becomes Director Emeritus","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Jay Venkatesan appointed to Board effective Feb 12, 2025; will serve as Audit Committee Chair and on Nominating/Governance Committee.","Venkatesan previously co-founded Alpine Immune Sciences (acquired by Vertex for $4.9B) and served as CEO of Angion Biomedica.","Dr. Milton Harris departs board effective Feb 11, 2025, becomes Director Emeritus and Chair of Scientific Advisory Board.","Harris is co-founder, instrumental in POZ Platform; departure not due to any disagreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176673,"accession_number":"0001708599-25-000013","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2025-02-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Serina Therapeutics closes $5M second tranche of equity financing at 113% premium","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received second $5M tranche of $10M equity financing from JuvVentures (UK) Limited.","Issued 500,000 shares at $10/share (113% premium to Jan 31 close of $4.70).","Issued warrants for 755,728 shares at $18.00 per share.","Funds to advance SER-252 (POZ-apomorphine) into Phase 1 trial in advanced Parkinson's in H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176672,"accession_number":"0001708599-25-000005","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2025-01-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Serina Therapeutics appoints Karen J. Wilson to board; Steven Mintz departs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Karen J. Wilson appointed effective Jan 14, 2025; over 30 years life sciences finance experience, CPA.","Wilson will serve as Compensation Committee Chair and on the Audit Committee.","Steven Mintz departs board; no disagreement; Remy Gross replaces as Audit Committee chair.","Wilson also serves on boards of Connect Biopharma, Elicio Therapeutics, and LAVA Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176671,"accession_number":"0001708599-25-000002","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Serina Therapeutics files investor presentation with preliminary 2024 data; no specific figures disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Exhibit 99.1 provides a presentation highlighting Serina's POZ Platform for drug delivery.","Filing states preliminary unaudited financial info as of Dec 31, 2024, but these figures are not included in the filing text or exhibit excerpt.","Presentation mentions RNA delivery and improved ADCs, but no revenue, cash, or other concrete financial metrics are given.","The company is an emerging growth company; audit of full-year 2024 results is ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193513,"accession_number":"0001708599-24-000033","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2024-12-26T23:59:59+00:00","items":["1.01","2.01","9.01"],"status":"ready","headline":"Serina sells UniverXome subsidiary to Juvenescence affiliate for $10 plus assumption of ~$11.2M debt","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sold UniverXome (holding ReCyte and Reverse Bio) to JuvVentures for $10 and assumption of ~$11.2M secured debt.","Juvenescence is Serina's largest shareholder; Special Committee approved with third-party valuation.","UniverXome owned 94.8% of ReCyte and 100% of Reverse Bio, legacy AgeX assets from pre-merger.","Intellectual property transfer not perfected; buyer bears future filing costs.","Company makes no warranty beyond express representations; assets fully encumbered by pre-existing debt to buyer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193512,"accession_number":"0001708599-24-000029","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2024-12-18T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Serina shareholders approve equity plan amendment increasing share reserve by 950,000 shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved Amendment to 2024 Equity Incentive Plan, increasing shares reserved by 950,000 to 2,675,000.","Amendment also provides for automatic annual share increase of 5% of outstanding shares from FY2026 through FY2034.","Directors elected: Balkrishan 'Simba' Gill (5,998,349 votes), Remy Gross (5,963,359), Steven Mintz (5,953,931).","Ratification of Frazier & Deeter as independent auditors approved with 7,162,782 votes for, 90,321 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193511,"accession_number":"0001493152-24-049549","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2024-12-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Serina Therapeutics presents data showing POZ-lipid avoids anti-PEG immune response in animal model","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["POZ-lipid did not induce IgM or IgG antibody responses after repeated administration in an animal model.","Standard PEG-lipids used in mRNA vaccines (Pfizer-BioNTech, Moderna) elicited robust IgM and IgG responses.","Anti-PEG responses are linked to hypersensitivity reactions including anaphylaxis; POZ-lipid may enable safer LNP formulations.","Randall Moreadith, MD, PhD, Chief Development Officer, presented at the 3rd Annual LNP Immunogenicity & Toxicity Summit in Boston."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193510,"accession_number":"0001493152-24-048316","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2024-12-02T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Serina Therapeutics secures $10M equity financing from Juvenescence at $10/share (120% premium)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Financing of 1M shares at $10/share, a 120% premium to Nov 26 closing price.","First $5M tranche received Nov 27, 2024; second $5M due by Jan 31, 2025.","Proceeds to advance SER-252 (POZ-apomorphine) into Phase 1 trial in advanced Parkinson's in H2 2025.","Juvenescence surrendered 755,728 post-merger warrants; received replacement incentive warrants exercisable at $18.","Special committee of independent directors approved the related-party transaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193509,"accession_number":"0001493152-24-044830","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Serina Therapeutics reports Q3 net income of $1.4M but raises going concern doubt as cash stands at $3.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $1.4M ($0.16 basic EPS) vs $1.8M a year ago; revenue $14k from NIH grants.","Operating expenses surged to $5.3M from $1.5M, driven by R&D and G&A increases.","Cash, cash equivalents, and restricted cash $3.2M; company expects insufficient funds for 12 months.","Expects ~$10M from Juvenescence warrant exercise via side letter, but still substantial doubt about going concern.","Lead candidate SER-252 (apomorphine) for Parkinson's planned for clinical testing in 2025; partnership with Enable Injections."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":70000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193508,"accession_number":"0001493152-24-039111","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2024-10-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Serina Therapeutics presents at Injectables Summit with Enable on SER-252 for Parkinson's","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Serina's CDO Randall Moreadith presents at 14th Annual Injectables Summit in Boston on October 2, 2024.","Joint presentation with Enable Injections' CCO Matthew Huddleston focuses on SER-252 for advanced Parkinson's disease.","Partnership combines Serina's SER-252 with Enable's enFuse wearable drug delivery platform.","No financial results, guidance, or other material corporate updates were provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209821,"accession_number":"0001493152-24-036080","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Serina Therapeutics appoints Steven Ledger as permanent CEO; base $450k, options grant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steven Ledger, interim CEO since March 2024, appointed permanent CEO effective Sept 8, 2024.","Annual base salary $450,000, increasing to $500,000 upon strategic goal; bonus up to 50% of base.","Received 501,851 stock options; 75% time-vested over 4 years, 25% performance-based.","Severance: 12 months base plus prorated bonus (min half) if terminated without cause.","Ledger has 35+ years experience; retains board seat."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209820,"accession_number":"0001493152-24-035028","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2024-09-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Serina Therapeutics to present at H.C. Wainwright conference on Sept 11","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Interim CEO Steve Ledger to present at H.C. Wainwright 26th Annual Global Investment Conference.","Presentation scheduled for September 11, 2024 at 12:00 p.m. ET.","Live webcast available via Investor section of Serina's website; replay available for limited time.","Serina is a clinical-stage biotech developing POZ Platform drug delivery technology."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209819,"accession_number":"0001493152-24-032700","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2024-08-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Serina Therapeutics appoints Gregory S. Curhan as CFO, replaces departing interim CFO Andrea Park","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gregory S. Curhan appointed CFO effective Aug 16, 2024; compensated at $650/hour plus 250k-share option vesting over 48 months.","Andrea Park, interim CFO and CAO, departs effective Aug 15, 2024.","Curhan is partner at FLG Partners and also CFO of Curevo Vaccines.","Option accelerates on change of control or $60M equity transaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209818,"accession_number":"0001493152-24-030996","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Serina Therapeutics reports Q2 net income $5.2M but warns of going concern doubt","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $5.2M ($0.61 basic EPS) includes $9.3M non-cash warrant revaluation; operating loss $3.8M.","Cash and restricted cash $6.1M at June 30; $11.2M owed to Juvenescence; substantial doubt about continuing as going concern.","Research and development expenses $1.6M (+$1.1M YoY); G&A $2.3M (+$1.8M YoY) partly from Merger costs.","Partnered with Enable Injections to develop SER-252 (POZ-apomorphine) for Parkinson's; IND planned for 2025.","Appointed Dr. Srini Tenjarla as SVP of CMC & Formulation; presented POZ-lipid immunogenicity data."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":56000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209817,"accession_number":"0001493152-24-029379","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2024-07-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Serina Therapeutics to present POZ-lipid data at mRNA Summit; no anti-PEG antibody response","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Randall Moreadith, MD, PhD, CDO, will present at 4th Annual mRNA-Based Therapeutics Summit in Boston, July 29-31, 2024.","POZ-lipid does not induce IgM or IgG antibody response in repeated in vivo dosing, unlike current PEG-lipids in mRNA vaccines.","This technology may reduce risk of serious adverse events like anaphylaxis linked to anti-PEG antibodies.","Presentation scheduled for 9:00 AM ET on Monday, July 29, 2024.","Serina's POZ Platform is being developed for neurological diseases, cancer, and other indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209816,"accession_number":"0001493152-24-028363","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2024-07-18T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Serina Therapeutics appoints Dr. Srini Tenjarla as SVP of CMC and Formulation","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Tenjarla joins from Takeda, where he was VP and Head of Drug Product Development.","At Takeda he oversaw phase-appropriate development from Phase 1 through validation.","Previously held leadership roles at Shire, including VP of Pharmaceutical Sciences.","He holds a Ph.D. in Pharmaceutical Sciences from the University of Houston.","Appointment effective July 15, 2024; will oversee CMC activities across pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209815,"accession_number":"0001493152-24-027113","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2024-07-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Serina Therapeutics COO Tacey Viegas to retire July 15; consulting agreement extends stock options","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Tacey Viegas notified retirement as COO effective July 15, 2024.","Separation agreement provides 12 months of base salary plus $1,000/month.","Consulting agreement extends options on 341,889 shares at $0.06 per share.","No other compensation under consulting agreement beyond option extension."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228017,"accession_number":"0001493152-24-023333","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Juvenescence exercises 377,865 warrants at $13.20 for $4.99M; remaining due Nov 2024 & June 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Juvenescence exercised 377,865 post-merger warrants at $13.20/share, generating $4,987,818 in proceeds.","Upon exercise, Juvenescence also received incentive warrants for 377,865 shares at $18.00, expiring March 26, 2028.","This exercise is one-third of total post-merger warrants; second third due by Nov 30, 2024, final third by June 30, 2025.","Proceeds will be used for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228016,"accession_number":"0001493152-24-019262","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Serina Therapeutics Q1 net loss $9.4M; going concern substantial doubt","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $9.4M ($3.38/share) vs net income of $1.7M in Q1 2023.","Cash, cash equivalents, and restricted cash total $8.8M as of March 31, 2024.","Company states cash not sufficient for 12 months, raising substantial doubt about going concern.","Juvenescence line of credit increased by $2.4M in March and $525k in May; total owed $10.4M.","Lead candidate SER-252 IND submission planned for 2025; Dr. Simba Gill appointed Executive Chairman."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":5000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228015,"accession_number":"0001493152-24-017731","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2024-05-03T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Serina Therapeutics replaces Withum with Frazier & Deeter as auditor after merger","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Audit committee approved Frazier & Deeter as independent auditor for FY2024, replacing Withum.","Withum's reports for FY2022 and FY2023 had no adverse opinion except going concern doubt.","No disagreements with Withum on accounting principles or audit scope during those periods.","Withum provided a letter (Exhibit 16.1) agreeing with the disclosures in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228014,"accession_number":"0001493152-24-015037","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2024-04-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Serina Therapeutics appoints Dr. Simba Gill as Executive Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Simba Gill appointed Executive Chairman effective April 12, 2024.","Annual cash fee of $300,000 and grant of 295,300 stock options under 2024 Equity Incentive Plan.","Dr. Gill has over 35 years of biotech leadership including Maxygen, Systemix, Boehringer Mannheim, Celltech.","Five-year post-termination non-compete and non-solicitation covenants apply."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228013,"accession_number":"0001493152-24-012530","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["2.01","1.01","9.01","2.03","3.03","5.01","5.02","5.03","8.01"],"status":"ready","headline":"AgeX completes reverse merger with Serina; becomes Serina Therapeutics, trades as SER","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger closed March 26, 2024; Serina shares converted at 0.97682654 per AgeX share; 5,913,277 shares issued to Serina stockholders.","Post-merger ~10.1M shares outstanding (fully diluted excl. warrants); Serina equityholders own ~75%, AgeX legacy ~25%.","AgeX changed name to Serina Therapeutics, Inc.; ticker changes from AGE to SER, new CUSIP 81751A108.","Board reconstituted: J. Milton Harris (Chair), Steven Ledger (Interim CEO & Dir), Andrea Park (Interim CFO), Randall Moreadith (CSO).","AgeX drew additional $2.4M under Juvenescence convertible note; transferred notes and certain assets to UniverXome in exchange for release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246780,"accession_number":"0001493152-24-011024","cik":1708599,"company_name":"Serina Therapeutics, Inc.","ticker":"SER","form_type":"8-K","filed_at":"2024-03-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AgeX Therapeutics reports FY2023 net loss $14.8M; cash only $0.3M; going concern doubt","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $14.8M in FY2023 vs $10.5M in FY2022; EPS ($13.73) vs ($9.70) (basic/diluted).","Cash and equivalents $0.3M at Dec 31, 2023; $4.5M owed to Juvenescence under line of credit.","Operating expenses rose to $10.1M from $7.0M, mainly due to merger due diligence and legal fees.","AgeX expresses substantial doubt about going concern; cash insufficient for next 12 months.","Stockholders approved merger with Serina Therapeutics; line of credit increased $4.4M, repayment extended to May 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":28474262.992999997,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-03-22T23:59:59+00:00|246780"}